跳至主要内容
临床试验/NCT06710977
NCT06710977已完成1 期

A Double-blind, Randomized Controlled Pilot Study Comparing the Safety and Efficacy of Intracameral Levofloxacin and Intracameral Cefazolin in Cataract Surgery

Tan Tock Seng Hospital2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
50
试验地点
2
主要终点
Number of Participants with Treatment related adverse events to Intracameral Cefazolin versus Levofloxacin

研究概览

简要总结

Patients with senile cataracts undergoing phacoemulsification were assigned to receive intracameral levofloxacin (0.1ml/0.5mg) or intracameral cefazolin (0.1ml/1mg). The primary endpoint was the occurrence of endophthalmitis during the 3 month follow-up period. Secondary endpoints included best-corrected visual acuity (BVCA), the presence of anterior chamber (AC) inflammation with grading of AC cells and presence of flare, along with intraocular pressure (IOP), corneal cell thickness (CCT), central foveal thickness (CFT) and cell density.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥50 to <80 years
  • Undergoing cataract surgery under the care of one of three study investigators, all of whom were consultant level cataract surgeons
  • Only those with senile cataracts, assessed using the Lens Opacities Classification System III scale (LOCS III) and without features of complex cataracts were included

排除标准

  • <50 or >80 years old
  • Prior ocular trauma, pregnant, previous history of refractive, corneal or intraocular surgery, cornea endothelial cell count <1500/sqmm², concomitant ocular disease, allergy to penicillin, fluoroquinolone or cephalosporin, and abnormal biometric measurements

研究组 & 干预措施

Safety of Intracameral levofloxacin in cataract surgery

Experimental

Eligible and recruited patients are randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery

干预措施: Safety of intracameral levofloxacin in cataract surgery (Drug)

Safety of Intracameral levofloxacin in cataract surgery

Experimental

Eligible and recruited patients are randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery

干预措施: Use of intracameral cefazolin in cataract surgery (Drug)

Use of intracameral cefazolin in cataract surgery

Active Comparator

Eligible and recruited patients were randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery

干预措施: Safety of intracameral levofloxacin in cataract surgery (Drug)

Use of intracameral cefazolin in cataract surgery

Active Comparator

Eligible and recruited patients were randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery

干预措施: Use of intracameral cefazolin in cataract surgery (Drug)

结局指标

主要结局

Number of Participants with Treatment related adverse events to Intracameral Cefazolin versus Levofloxacin

时间窗: From cataract surgery through to study completion, an average of 1 year

次要结局

未报告次要终点

研究者

发起方
Tan Tock Seng Hospital
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验